5,6-MDO-MiPT

Last updated
5,6-MDO-MiPT
5,6-MDO-MiPT.svg
Clinical data
Other names5,6-Methylenedioxy-N-methyl-N-isopropyltryptamine
Routes of
administration 		Oral [1]
ATC code
  • None
Pharmacokinetic data
Onset of action Unknown [1]
Duration of action Unknown [1]
Identifiers
  • N-[2-(5H-[1,3]dioxolo[4,5-f]indol-7-yl)ethyl]-N-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C15H20N2O2
Molar mass 260.337 g·mol−1
3D model (JSmol)
  • CC(C)N(C)CCC1=CNC2=CC3=C(C=C21)OCO3
  • InChI=1S/C15H20N2O2/c1-10(2)17(3)5-4-11-8-16-13-7-15-14(6-12(11)13)18-9-19-15/h6-8,10,16H,4-5,9H2,1-3H3
  • Key:OZKGXOZBACDFIQ-UHFFFAOYSA-N

5,6-MDO-MiPT, or 5,6-methylenedioxy-N-methyl-N-isopropyltryptamine, is a lesser-known chemical compound of the tryptamine family. [1] It is the 5,6-methylenedioxy derivative of methylisopropyltryptamine (MiPT) and an analogue of 5-MeO-MiPT. [1] In his 1991 book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin lists the dose range as greater than 50 mg orally and its duration as unknown. [1] The drug produced few to no effects, with effects including parasthesia and lightheadedness, at doses of up to 75 mg orally. [1] 5,6-MDO-MiPT was first described in the scientific literature by 1982. [2]

Contents

See also

References

  1. 1 2 3 4 5 6 7 Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN   0-9630096-9-9. OCLC   38503252.
  2. ↑ Grotjahn, Douglas B. (1983). "Synthesis and characterization of 5 H ‐1,3‐dioxolo[4,5‐ f ]indoleethylamines". Journal of Heterocyclic Chemistry. 20 (4): 1031–1036. doi:10.1002/jhet.5570200438. ISSN   0022-152X . Retrieved 4 November 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.